Institut für Transfusionsmedizin und Immunhämatologie
Univ.-Prof. Dr. med. habil. Dr. med. Halvard B. Bönig, M.A.
Arzt für Kinderheilkunde und Jugendmedizin, Arzt für Transfusionsmedizin

Abteilung
Forschung und Entwicklung - Translationale Zelltherapeutikaentwicklung/GMP

Beruflicher Werdegang

1989-1996
Studium der Anglistik, Kunstgeschichte und Medizin an der Heinrich-Heine-Universität Düsseldorf, St. Bartholomew's Hospital Medical School, London, und University of Tennessee, Memphis TN
 
1995
Magister Artium Anglistik und Kunstgeschichte
 
1996
Med. Staatsexamen
 
1998
Promotion zum Dr. med. an der Medizinischen Fakultät der Heinrich-Heine-Universität Düsseldorf
 
1997-2002
Wissenschaftlicher Mitarbeiter (Arzt in der Weiterbildung) am Zentrum für Kinderheilkunde und Jugendmedizin der HHU Düsseldorf; Facharztprüfung zum Arzt für Kinderheilkunde und Jugendmedizin
 
2002-2004
Senior Research Fellow im Labor von Prof. Papayannopoulou, University of Washington, Seattle, WA
 
2005-2007
Acting Assistant Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
2007-2009
Wissenschaftlicher Mitarbeiter beim DRK-Blutspendedienst BaWüHe, Institut Frankfurt
 
2008-2011
Affiliate Assistant Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
2009-2013
Leiter der Abteilung für Zelltherapeutika / Cell Processing (GMP), Institut für Transfusionsmedizin und Immunhämatologie Frankfurt a.M.
 
2011-2018
Affiliate Associate Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
2012
Ruf (primo loco) auf die W3 Professur für Translationale Entwicklung von Zelltherapeutika an der Goethe Universität, Frankfurt (angenommen)
 
2013
Habilitation im Fach Experimentelle Hämatologie zum Dr. med. habil.
 
2015
Ruf (primo loco) auf die W3 Professur mit Institutsleitung, Institut für Transfusionsmedizin, Otto-von-Guericke Universität Magdeburg (abgelehnt)
 
seit 2018
Affiliate Professor of Medicine/Hematology, University of Washington, Seattle, WA
 
Aktuell:
Professor (W3) für Translationale Entwicklung von Zelltherapeutika am Institut für Transfusionsmedizin und Immunhämatologie, Fachbereich Medizin, Johann-Wolfgang-Goethe Universität, Frankfurt
Leiter Herstellung Experimentelle Zelltherapeutika und Sachkundige Person, DRK-Blutspendedienst BaWüHe, Institut Frankfurt
 

Mitgliedschaften in wissenschaftlichen Fachgesellschaften (ausgewählt)

  • American Association of Blood Banks
  • American Society of Hematology
  • International Society of Blood Transfusion
  • International Society of Experimental Hematology

Ausgewählte Publikationen (seit 2015)

  • 93. Bonig H, Becker PS, Schwebig A, Turner M (2015) Biosimilar G-CSF for healthy donor stem cell mobilization: need we be afraid? Transfusion 55:430-9 featured in: http://transfusionnews.com/2015/02/15/video-biosimilar-granulocyte-colony-stimulating-factor/ editorial in: Abi-Raad R, Smitch BR: Biosimilar biologics: never identical but close enough. Transfusion 55:229–231
  • 94. Chudziak D, Spohn G, Karpova D, Dauber K, Wiercinska E, Miettinen J, Papayannopoulou T, Bonig H (2015) Functional consequences of perturbed CXCL12 signal processing: Analyses of immature hematopoiesis in GRK6-deficient mice. Stem Cells and Development 24:737-46
  • 95. Henrich D, Verboket R, Schaible A, Wilhelm K, Oppermann E, Brune JC, Bonig H, Nau C, Meier S, Marzi I, Seebach C (2015) Characterization of bone marrow mononuclear cells on biomaterials for bone tissue engineering in vitro. BioMed Research International 2015:762407
  • 96. Kays SK, Kaufmann KB, Abel T, Brendel C, Bonig H, Grez M, Buchholz CJ, Kneissl S (2015) CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells. Stem Cells Dev 24:714-23
  • 97. Sorg N, Poppe C, Bunos M, Wingenfeld E, Hümmer C, Krämer A, Stock B, Seifried E, Bonig H (2015) Erythrocyte depletion from bone marrow and peripheral blood buffy coat – a comparison of two new and three established technologies Transfusion 55:1275-82
  • 98. Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bonig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS (2015) Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Antigen Receptor. Mol Ther 23:330-8
  • 99. Bonig H and Kim YM (2015) VLA4 in Acute Lymphoblastic Leukemia; in: Andreeff, M (ed.): Targeted Therapy of Acute myeloid Leukemias, Springer, New York, NY. ISBN: 978-1-4939-1392-3
  • 100. Arnold C, Gispert S, Bonig H, von Wegner F, Somasundaram S, Kell CA (2015) Dopaminergic modulation of cognitive preparation for overt reading: Evidence from the study of genetic polymorphisms. Cerebral Cortex 26:1539-57
  • 101. Kraft D, Rall M, Volcic M, Metzler E, Groo A, Stahl A, Bauer L, Nasonova E, Salles D, Taucher-Scholz G, Bonig H, Fournier C, Wiesmüller L (2015) NF-kB-dependent DNA damage-signaling differentially regulates DNA double-strand break repair mechanisms in immature and mature human hematopoietic cells. Leukemia 29:1543-54
  • 102. Seebach C, Henrich D, Schaible A, Relja B, Jugold M, Bonig H, Marzi I. (2015) Cell based therapy by implanted humane bone marrow-derived mononuclear cells (BMC) improved bone healing of large bone defects in rats. Tissue Eng Part A. 21:1565-78
  • 103. Schulz M*, Karpova D*, Spohn G, Damert A, Seifried E, Binder V*, Bonig H* (2015) Variant rs1801157 in the 3’UTR of SDF-1ß does not explain variability of healthy-donor G-CSF responsiveness. PLOSOne 10:e0121859 *equal contribution
  • 104. Zirafi O, Kim KA, Staendker L, Mohr KB, Sauter D, Heigele A, Kluge SF, Wiercinska E, Chudziak D, Richter R, Moepps B, Gierschik P, Vas V, Geiger H, Lamla M, Weil T, Burster T, Zgraja A, Daubeuf F, Frossard N, Hachet-Haas M, Heunisch F, Reichetzeder C, Galzi JL, Castells JP, Canales-Mayordomo A, Jimenez-Barbero J, Gimenez-Gallego G, Schneider M, Shorter J, Telenti A, Hocher B, Forssmann WG, Bonig H, Kirchhoff F, Muench J (2015) Discovery and characterization of an endogenous CXCR4 antagonist. Cell Reports 11:737-47
  • 105. Bunos M, Hümmer C, Wingenfeld E, Sorg N, Seifried E, Bonig H (2015) Automated isolation of primary antigen-specific T-cells from donor lymphocyte concentrates. Vox Sanguinis 109:387-93
  • 106. Spohn G, Wiercinska E, Karpova D, Bunos M, Hümmer C, Wingenfeld E, Sorg N, Poppe C, Huppert V, Stutz J, Reck K, Essl M, Seifried E, Bonig H (2015) Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. Cytotherapy 17:1465-71
  • 107. Kuvardina ON, Herglotz J, Kolodziej S, Kohrs N, Herkt S, Wojcik B, Oellerich T, Serve H, Bonig H, Stocking C, Rieger MA, Lausen J (2015) RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation. Blood 125:3570-9
  • 108. Karpova D, Bonig H (2015) CXCR4/CXCL12 signaling in immature hematopoiesis – lessons from pharmacological and genetic models. Stem Cells 33:2391-9
  • 109. Pfirrmann V, Oselsner S, Rettinger E, Huenecke S, Wels WS, Bonig H, Cinatl J, Schubert R, Klingebiel T, Bader P (2015) CMV-specific cytokine-induced killer (CIKp65) cells: Concurrent targeting of leukemia and cytomegalovirus. Cytotherapy 17:1139-51
  • 110. Straetemans T, Grunder C, Heijhuurs S, Hol S, Slaper-Cortenbach I, Bonig H, Sebestyen Z, Kuball J (2015) Untouched GMP-ready purified engineered immune cells to treat cancer. Clin Cancer Res. 21:3957-68
  • 111. Bacher P*, Jochheim-Richter A*, Mockel-Tenbrink N, Kniemeyer O, Wingenfeld E, Alex R, Karpova D, Ortigao A, Lehrnbecher T, Ullman A, Seifried E, Brakhage AA, Assenmacher M, Bonig H*, Scheffold A* (2015) Clinical-scale isolation of the total Aspergillus fumigatus-reactive T helper cell repertoire for adoptive transfer. Cytotherapy 17:1396-405 * contributed equally
  • 112. Latifi-Pupovci H; Kuci Z, Wehner S, Bonig H, Lieberz R, Klingebiel T, Bader P, Kuci S (2015) Wound healing potential of mesenchymal stromal cells generated from human CD271+ bone marrow mononuclear cells. Journal of Translational Medicine 13:315
  • 113. Rall M, Kraft D, Volcic M, Groo A, Nasonova E, Taucher-Scholz G, Bonig H, Wiesmuller L, Fournier C (2015) Impact of charged particle exposure on homologous DNA double-strand break repair in human blood-derived cells. Front Oncol 5:520
  • 114. Chow K, Luxembourg B, Seifried E, Bonig H (2016) Spleen size is significantly influenced by body height and gender: Establishment of normal values for spleen size by ultrasound based on a cohort of 1200 normal healthy individuals. Radiology 279:306-13 Featured in: Dtsch Arztebl 2016; 113(4): A-143 Featured in: Transfusionsmedizin 2016;6:53
  • 115. Schulz M and Bonig H (2016) Update on biosimilars of G-CSF – when no news is good news. Current Opinion in Hematology 23:61-6
  • 116. Rettinger E, Huenecke S, Bonig H, Merker M, Jarisch A, Soerensen J, Willasch A, Bug G, Schulz A, Klingebiel T, Bader P (2016) IL-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy. Hematologica 101:153-6
  • 117. Winkler IG, Wiercinska E, Barbier V, Nowlan B, Bonig H, Levesque JP (2016) Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak. Exp Hematol 44:303-14
  • 118. Assmus B, Alakmeh S, De Rosa S, Bonig H, Hermann E, Levy WC, Dimmeler S, Zeiher AM (2016) Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT. Eur Heart J. 37:1659-66
  • 119. Hummer C, Poppe C, Bunos M, Stock B, Wingenfeld E, Huppert V, Stuth J, Reck K, Essl M, Seifried E, Bonig H (2016) Automation of cellular therapy product manufacturing: Results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure. J Transl Med 14:76
  • 120. Kohrs N, Kolodziej S, Kuvardina ON, Herglotz J, Yillah J, Herkt S, Piechatzek A, Riester GS, Lingner T, Wichmann C, Bonig H ,Seifried E, Platzbecker U, Medyouf H, Grez M, Lausen J (2016) MiR144/451 expression is repressed by RUNX1 during megakaryopoiesis and disturbed by RUNX1/ETO. PLOS Genetics 12(3):e1005946
  • 121. Huenecke S, Bremm M, Cappel C, Esser R, Quaiser A, Bonig H, Jarisch A, Soerensen J, Klingebiel T, Bader P, Koehl U (2016) Optimization of individualized graft composition: CD3/CD19 depletion combined with CD34 selection for haploidentical transplantation. Transfusion 56:2336-45
  • 122. Kuci Z*, Bonig H*, Kreyenberg H, Bunos M, Jauch A, Janssen JWG, Skific M, Michel K, Eising B, von Luettichau I, Schulz A, Sykora KW, Jarisch A, Soerensen J, Salzmann-Manrique E, Seifried E, Klingebiel T, Bader P*, Kuci S* (2016) Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica 101(8):985-94 *equal contribution
  • 123. Thiel U, Wawer A, von Luettichau I, Bender HU, Blaeschke F, Grunewald TGP, Steinborn M, Röper B, Bonig H, Klingebiel T, Bader P, Koscielniak E, Paulussen M, Dirksen U, Juergens H, Kolb HJ, Burdach SEM (2016) Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma (AES) patients with fatal outcome irrespective of therapy in contrast to curable AES patients with multiple bone metastases but unaffected marrow. Oncotarget doi: 10.18632/oncotarget.10938
  • 124. Bremm M, Huenecke S, Zimmermann O, Pfirrmann V, Quaiser A, Bonig H, Soerensen J, Klingebiel T, Rettinger E, Bader P, Cappel C (2016) In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CSA) on cytokine induced killer (CIK) cell immunotherapy. J Transl Med 14:264
  • 125. Bonig H and Muller I (2016) Feasibility of CD3/CD19 depletion of a bone marrow graft. Cytotherapy 18:1345-7
  • 126. Becker PS, Schwebig A, Brauninger S, Bialleck H, Luxembourg B, Schulz M, Tsamadou C, Wiesneth M, Reinhardt P, Mytilineos J, Seidl C, Gattu S, Kaliakina N, Singh P, Schrezenmeier H, Seifried E, Bonig H (2016) Healthy donor hematopoietic stem cell mobilization with biosimilar G-CSF: Safety, efficacy and graft performance. Transfusion 56:3055-3064
  • 127. Seebach C, Henrich D, Meier S, Nau C, Bonig H, Marzi I (2016) Safety and feasibility of cell-based therapy with autologous bone marrow-derived mononuclear cells in plate-stabilized proximal humeral fractures in humans. J Transl Med 14:314
  • 128. Bremm M, Brehm C, Erben S, Jarisch A, Schumm M, Arendt A, Bonig H, Klingebiel T, Koehl U, Bader P, Huenecke S (2017) Generation and flow cytometric quality control of TCR??/CD19-depleted grafts. Cytometry Part B 92:126-135
  • 129. Walter R, Pan KT, Doebele C, Comoglio F, Tomska K, Bohnenberger H, Young RM, Jacobs L, Keller U, Bonig H, Engelke M, Rosenwald A, Urlaub H, Staudt LM, Serve H, Zenz T, Oellerich T (2017) HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B cell receptor signaling. Blood 129:598-608
  • 130. Karpova D, Braeuninger S, Wiercinska E, Kraemer A, Stock B, Graff J, Martin H, Wach A, Escot C, Douglas G, Romagnolil B, Chevalier E, Dembowski K, Hooftman L, Bonig H (2017) Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers – results of a dose escalation trial. J Transl Med 15:2
  • 131. Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshimipathi S, Martin K, Bunjes D, von Harsdorf S, Weissnger E, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch D, Grigoleit GU (2017) Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT. Leukemia 31:2161-2171
  • 132. Duchartre Y, Bachl S, Kim HN, Gang EJ, Lee S, Liu HC, Shung K, Xu R, Kruse A, Tachas G, Bonig H, Kim YM. (2017) Effects of CD49d-targeted antisense-oligonucleotide on ?4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies. PLoS One. 12:e0187684.
  • 133. Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Goellner S, Rouhi A, Palmqvist L, Rieger MA, Bonig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T (2017) Hoxa9 and Meis1 cooperatively induce addiction to Syk signaling by suppressing miR-146a in acute myeloid leukemia. Cancer Cell 31:549-562
  • 134. Richter C, Herrero San Juan M, Weigmann B, Bergis D, Dauber K, Muders MH, Baretton GB, Pfeilschifter JM, Bonig H, Brenner S, Radeke HH (2017) Defective IL-23/IL-17 axis protects p47phox-/- mice from colon cancer. Front Immunol 8:44
  • 135. Bonig H and Bug G (2017) Red blood cell depletion from a peripheral blood stem cell graft. Bone Marrow Transplant. doi:10.1038/bmt.2017.72 [Epub ahead of print]
  • 136. Kuvardina ON, Herkt S, Yillah J, Kohrs N, Bonig H, Seifried S, Müller-Tidow C, Lausen J (2017) Hematopoietic transcription factors and differential cofactor binding regulate PRKACB isoform expression. Oncotarget 8:71685-71698
  • 137. Karpova D, Ritchey J, Holt M, Monlish D, Batoon L, Millard A, Spohn G, Wiercinska E, Chendamarai E, Yang W, Schuettpelz LG, Dembowsky K, Pettit AR, Rettig M, Bonig H*, DiPersio JF* (2017) Continuous blockade of CXCR4 results in dramatic mobilization and expansion of murine hematopoietic stem and progenitor cells. Blood 129:2939-2949 *equal contribution
  • 138. Shin S, Kim J, Kim-Wanner SZ, Bonig H, Cho ST, Kim S, Choi JR, Lee KA (2017) A novel association between relaxin receptor polymorphism and hematopoietic stem cell yield after mobilization. PLoS One 12:e0179986
  • 139. Kim-Wanner SZ, Bug G, Steinmann J, Ajib S, Sorg N, Poppe C, Bunos M, Wingenfeld E, Hümmer C, Luxembourg B, Seifried E, Bonig H (2017) Erythrocyte depletion from bone marrow – performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC. J Transl Med 15:174
  • 140. Kohlscheen S, Bonig H, Modlich U (2017) Promises and Challenges in Hematopoietic Stem Cell Gene Therapy. Hum Gene Ther. 28:782-799.
  • 141. Nowakowska P, Romanski A, Miller N, Odendahl M, Bonig H, Zhang C, Seifried E, Wels WS, Tonn T. (2018) Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol Immunother. 67:25-38.
  • 142. Herkt SC, Kuvardina ON, Herglotz J, Schneider L, Meyer A, Pommerenke C, Salinas-Riester G, Seifried E, Bonig H, Lausen J. (2018) Protein arginine methyltransferase 6 controls erythroid gene expression and differentiation of human CD34+ progenitor cells. Haematologica. 103:18-29.
  • 143. Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, Tangelder M, Castaman G, Schwäble J, Bonig H, Seifried E, Cattaneo F, Meyer C, Leebeek FWG. (2018) Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 131:1022-1031
  • 144. Verboket R, Leiblein M, Seebach C, Nau C, Janko M, Bellen M, Bonig H, Henrich D, Marzi I. (2018) Autologous cell-based therapy for treatment of large bone defects: from bench to bedside. Eur J Trauma Emerg Surg. 2018 Jan 19. doi: 10.1007/s00068-018-0906-y. [Epub ahead of print]
  • 145. Bader P*, Kuçi Z*, Bakhtiar S, Basu O, Bug G, Dennis M, Greil J, Barta A, Kállay KM, Lang P, Lucchini G, Pol R, Schulz A, Sykora KW, von Luettichau I, Herter-Sprie G, Uddin MA, Jenkin P, Alsultan A, Buechner J, Stein J, Kelemen A, Jarisch A, Soerensen J, Salzmann-Manrique E, Hutter M, Schäfer R, Seifried E, Klingebiel T, Bonig H*, Kuçi S*. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplant. 2018 Jan 29 [e-pub ahead of print]. *equal contribution
  • 146. Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, Hudecek M. (2018) CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 32:1168-1179.
  • 147. Müller N, Landwehr K, Langeveld K, Stenzel J, Pouwels W, van der Hoorn MAWG, Seifried E, Bonig H. (2018) Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells. Cytotherapy. 20:532-542.
  • 148. Holstein M, Mesa-Nuñez C, Miskey C, Almarza E, Poletti V, Schmeer M, Grueso E, Ordóñez Flores JC, Kobelt D, Walther W, Aneja MK, Geiger J, Bonig HB, Izsvák Z, Schleef M, Rudolph C, Mavilio F, Bueren JA, Guenechea G, Ivics Z. (2018) Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors. Mol Ther. 26:1137-1153.
  • 149. Henrich D, Seebach C, Verboket R, Schaible A, Marzi I, Bonig H. (2018) The osteo-inductive activity of bone-marrow-derived mononuclear cells resides within the CD14+ population and is independent of the CD34+ population. Eur Cell Mater. 35:165-177.
  • 150. Pfeffermann LM, Pfirrmann V, Huenecke S, Bremm M, Bonig H, Kvasnicka HM, Klingebiel T, Bader P, Rettinger E. (2018) Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma. Cytotherapy. 2018 May 10. pii: S1465-3249(18)30509-7. doi: 10.1016/j.jcyt.2018.04.005. [Epub ahead of print]
  • 151. Stenzinger M, Bonig H (2018) Risks of leukapheresis and how to manage them – a non-systematic review. Transfusion and Apheresis Science. (in press)
  • 152. Rojewski M, Schafer R, Bieback K, Schrezenmeier H, Bonig H (2018) Mesenchymale Stromazellen auf dem Weg zur klinischen Anwendung: Update 2018 [Mesenchymal Stromal Cells on Their Way from Bench to Bedside: Update 2018]. Transfusionsmedizin. 8:148-59

(zuletzt aktualisiert 08.10.2018)

Univ.-Prof. Dr. med. Halvard B. Bönig, MA

Univ.-Prof. Dr. med. Halvard B. Bönig, MA
Professur für Translationale Entwicklung von Zelltherapeutika

Institut für Transfusionsmedizin und Immunhämatologie Fachbereich Medizin,
Johann-Wolfgang-Goethe Universität
und DRK-Blutspendedienst Baden-Württemberg-Hessen,
Institut Frankfurt am Main
Sandhofstrasse 1
60528 Frankfurt
Tel.: 069 / 6782-177

E-Mail: